Navigation Links
Clive Dix Appointed as Chairman of Crescendo Biologics
Date:1/8/2010

CAMBRIDGE, England, January 8 /PRNewswire/ -- Crescendo Biologics ("Crescendo") today announces the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent GBP4.5 million seed round fundraising.

Dr Dix has an exceptional track record established over more than 20 years in the pharmaceutical and biotechnology business. He is the Chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector, and was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006. Prior to running PowderMed, Dr Dix was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Dr Dix began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001. Dr Dix is non-Executive Chairman of Modern Biosciences plc and Auralis Ltd.

Dr Dix has an in-depth understanding of all facets of the drug discovery and development process, having led projects and portfolios from conception through to Phase III in a range of therapeutic areas including cardiovascular, respiratory, inflammatory and infectious diseases.

Clive Dix said, "The antibody space remains enormously attractive for pharmaceutical and biotechnology companies. Current products have brought real benefits to patients and command huge market value, and there is a great demand for innovative antibody technologies to deliver the high value products of the future. With substantial seed funding in place, Crescendo has the opportunity to build on its world class, proprietary technology platforms and grow to become a leader in next-generation antibody therapeutics."

Handing over the Chairman's reins, lead investor Graziano Seghezzi said, "Independent leadership is what we strive for at Sofinnova when we build our companies' board of directors. I am delighted to have someone of Clive's calibre join the Company and Board."

Mike Romanos said, "Clive's experience will be invaluable as we grow our business through technology development, in-house projects and future partnership programmes. I look forward to working together."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. http://www.crescendobiologics.com

    Contacts

    Mike Romanos / Amanda Bettison
    Crescendo Biologics
    Tel: +44(0)1223-497140
    Email: mromanos / abettison@crescendobiologics.com

    Chris Gardner
    Citigate Dewe Rogerson
    Tel: +44(0)207-638-9571
    Email: chris.gardner@citigatedr.co.uk

SOURCE Crescendo Biologics Ltd


'/>"/>
SOURCE Crescendo Biologics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
2. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
3. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
4. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
5. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
6. Al Novak Elected Chairman of the Board of OrbusNeich Medical
7. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
8. Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman
9. Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
10. Bracken to Become Chairman of HCAs Board of Directors Effective Dec. 15
11. Stryker Announces Change in Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Februar 2017 ITL Limited, ( ASX: ... ist erfreut, für das zum 31. Dezember 2016 ... exzellente Ergebnisse vorlegen zu können. Eine vollständige Präsentation ... finden Sie hier . ... 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current ... will soon begin franchising throughout the U.S. starting this spring. Current Meditation focuses ... practice of meditation mainstream. Current Meditation will be the first meditation concept in ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Top ... Smiling Patriot program today with a new Indiegogo campaign . Individuals ... to homeless veterans in the Los Angeles area, either as a participating patient or ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it ... healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s ... systems recently invested $51 million to purchase and renovate the 185,000 square-foot office ...
Breaking Medicine News(10 mins):